Pharma BD Deal Intelligence
Stryker announced a definitive agreement on January 6, 2025 to acquire all issued and outstanding shares of Inari Medical for $80.00 per share in cash, a total fully diluted equity value of approximately $4.9 billion. The transaction gives Stryker entry into the peripheral vascular segment through Inari's mechanical thrombectomy portfolio for deep vein thrombosis and pulmonary embolism. Both boards unanimously approved the deal, which was expected to close by the end of Q1 2025 subject to customary conditions. Status recorded as of announcement.
← Browse all deals · How we score deals
More: 2025 deals · Stryker Corporation deals